Molybdenum
The sulfite-clearing cofactor metal you almost never run short on
Moderate evidence
🧂Mineral
Evidence tier
Moderate
Research weight
Citations
9 verified / 9
Classification
Mineral
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.
What is Molybdenum?
Molybdenum is a mineral used for corrects rare deficiency: reverses sulfur-amino-acid intolerance, tachycardia and neurologic symptoms in patients on long-term molybdenum-free parenteral nutrition (single documented case, resolved with iv molybdate). NutriDex grades the human evidence as Moderate. Molybdenum is an essential trace mineral that, as the molybdopterin cofactor, enables four enzymes—sulfite oxidase, xanthine oxidase, aldehyde oxidase, and mARC—most critically detoxifying sulfite from sulfur-amino-acid metabolism. True dietary deficiency is essentially unknown in free-living people; the only documented case occurred during prolonged molybdenum-free parenteral nutrition, and the inborn molybdenum cofactor deficiency (a genetic, not dietary, disorder) causes fatal neonatal neurodegeneration treatable only with fosdenopterin, not dietary molybdenum. Controlled depletion studies show humans stay in balance on as little as ~22 mcg/day, so the typical diet vastly exceeds needs. There are no credible RCTs showing benefit from molybdenum supplements in non-deficient people; supplementation should be regarded as correcting a (rare) deficiency rather than improving health.
Purported Benefits
✓Corrects rare deficiency: reverses sulfur-amino-acid intolerance, tachycardia and neurologic symptoms in patients on long-term molybdenum-free parenteral nutrition (single documented case, resolved with IV molybdate)
✓Essential cofactor for sulfite oxidase—prevents accumulation of toxic sulfite/S-sulfocysteine from cysteine and methionine metabolism
✓Cofactor for xanthine oxidase—required for purine catabolism and uric acid formation
✓Cofactor for aldehyde oxidase and mARC—participates in metabolism of aldehydes, certain drugs, and detoxification of N-hydroxylated compounds
✓Higher molybdenum status is associated (observational, not causal) with lower serum uric acid and reduced hyperuricemia/gout prevalence in NHANES
✓No demonstrated benefit of supplementation in people who already meet intake (the overwhelming majority)
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Corrects rare molybdenum deficiency (long-term TPN)Single documented TPN case reversed by IV molybdate; deficiency essentially unknown in free-living people. | Preliminary | ↑ benefit · large | 1 |
| Maintains essential enzyme cofactor function (sulfite oxidase etc.)Well-established biochemistry: required cofactor preventing toxic sulfite accumulation; not a supplement benefit per se. | Strong | ↑ benefit · large | 1 |
| Lower hyperuricemia/gout risk with higher statusSingle NHANES cross-sectional study links higher urinary molybdenum to less gout; associational only, not causal. | Preliminary | ↑ benefit · small | 1 |
| Benefit of supplementation in already-replete peopleBalance studies show needs are tiny and easily met by diet; no RCT shows benefit beyond adequate intake. | No Evidence | — no effect · negligible | 1 |
Dosing & Compounds
Typical Dose
Adult RDA (US): 45 mcg/day for men and women (pregnancy/lactation 50 mcg/day). EFSA sets an Adequate Intake of 65 mcg/day for adults. Typical Western intakes (~75-250 mcg/day) already exceed needs, and balance is maintained at ~22 mcg/day. Supplement doses are usually small (45-100 mcg). Tolerable Upper Intake Level (UL): 2,000 mcg (2 mg)/day for adults.
Active Compounds
Safety & Cautions
Low toxicity at dietary levels; deficiency is essentially nonexistent outside parenteral nutrition, so routine supplementation is unnecessary. UL is 2,000 mcg/day, derived largely from animal reproductive/growth toxicity (human data are limited). Very high occupational and dietary exposures have been linked to gout-like syndromes and elevated uric acid in some reports, consistent with molybdenum's role in xanthine oxidase. The major interaction is with COPPER: molybdenum (especially as tetrathiomolybdate) antagonizes copper absorption and bioavailability—this is exploited therapeutically to lower copper in Wilson disease, but means high molybdenum intake can theoretically worsen copper status. Molybdenum cofactor deficiency is a genetic enzyme-synthesis disorder that does NOT respond to dietary molybdenum and requires fosdenopterin (cyclic pyranopterin monophosphate). No important drug interactions are established at nutritional doses. Educational only — always check with your doctor or pharmacist before combining Molybdenum with any medicine.
Key Studies
systematic review
Mendez et al. (GeneReviews 2022)
✓ Full text
Reviews molybdenum cofactor deficiency as an autosomal-recessive, usually fatal neonatal neurodegenerative disorder from loss of sulfite oxidase, causing toxic sulfite and S-sulfocysteine accumulation—genetic, not nutritional.
clinical trial
Brewer et al. (Arch Neurol / Wilson disease TM trials)
✓ PubMed
Ammonium tetrathiomolybdate strongly lowers free serum copper (to ~one-quarter of baseline over 8 weeks), demonstrating the clinically exploited molybdenum-copper antagonism relevant to copper-status interactions.
Review
Carretta 2026
✓ PubMed
Endovascular therapy versus best medical treatment in pediatric acute ischemic stroke: A systematic review and meta-analysis
observational cohort (NHANES)
Zhang et al. (NHANES, PMC 2024)
✓ Full text
Cross-sectional study of US adults (NHANES 1999-2016) found highest urinary molybdenum quartile associated with lower hyperuricemia (OR 0.73, 95% CI 0.64-0.83) and gout (OR 0.71, 95% CI 0.52-0.94)—associational only.
authoritative body
NIH ODS Fact Sheet (2023)
✓ Source
Sets adult RDA at 45 mcg/day and Tolerable Upper Intake Level at 2,000 mcg/day; identifies legumes as the richest dietary source and notes molybdenum is cofactor for sulfite oxidase, xanthine oxidase, aldehyde oxidase, and mARC.
clinical study vs historical control
Schwarz et al. (J Inherit Metab Dis 2025)
✓ PubMed
In molybdenum cofactor deficiency type A, fosdenopterin (synthetic cPMP) reduced risk of death by 82% vs genotype-matched historical controls—an enzyme-cofactor disorder unresponsive to dietary molybdenum.
case report
Abumrad et al. (AJCN 1981)
✓ PubMed
The only documented dietary molybdenum deficiency: a TPN patient developed high methionine, low uric acid, high urinary thiosulfate, tachycardia and neurologic symptoms, all reversed by IV ammonium molybdate.
authoritative body
EFSA NDA Panel (2013)
✓ Source
Concluded data were insufficient to derive a requirement and set an Adequate Intake of 65 mcg/day for adults based on observed European intakes, also applying to pregnancy and lactation.
controlled metabolic study
Turnlund et al. (AJCN 1995)
✓ PubMed
In 4 young men fed 22 mcg/day Mo for 102 days, molybdenum balance was near zero, and kinetic modeling estimated ~43 mcg/day suffices to maintain steady-state plasma molybdenum—showing requirements are very low.